China Palmoplantar Pustulosis (PPP) Market, By Disease Type (Type A and Type B), Severity (Mild-Moderate and Moderate-Severe), Diagnosis (Laboratory Tests, Skin Biopsy), Treatment (Emollients, Topical Steroids, Coal tar, Phototherapy), Population Type (Children and Adults), Route Of Administration (Oral, Topical and Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
China Palmoplantar Pustulosis (PPP) Market Analysis and Size
Growing incidence of palmoplantar pustulosis and increasing women population are the primary factors that boosted the market demand in the forecast period 2023-2030. Several research stated that up to 90% of people suffering from the skin condition, smoke or once did. This disease can occur in any age group. But it mostly occurs in women than men, and it's most frequently found in people between the ages40 and 60 years old. Therapeutics of palmoplantar pustulosis does not cure the disorder properly and is not always successful.
Data Bridge Market Research analyses a growth rate in the palmoplantar pustulosis (PPP) market in the forecast period 2023-2030. The expected CAGR of palmoplantar pustulosis (PPP) market is tend to be around 5.60% in the mentioned forecast period. The market is valued at USD 82.01 million in 2022, and it would grow upto USD 126.8 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
China Palmoplantar Pustulosis (PPP) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Type A and Type B), Severity (Mild-Moderate and Moderate-Severe), Type (Diagnosis and Treatment), Population Type (Children and Adults), Route Of Administration (Oral, Topical and Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Market Players Covered
|
Novartis AG (Switzerland), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), AstraZeneca (U.K.), GSK plc (U.K.), Merck & Co., Inc. (U.S.), Amgen inc. (U.S.), AnGes, Inc. (Japan), Johnson & Johnson Private Limited (U.S.), AbbVie Inc. (U.S.), Perrigo Company plc (Ireland), WOCKHARDT (India), Bausch Health Companies Inc. (Canada), Viatris Inc. (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Xiromed (U.S.) and Encube Ethicals Private Limited (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Palmoplantar pustulosis is a type of uncommon chronic pustular condition affecting the palms and soles. It is also known as pustulosis palmaris et plantaris. It is associated to a common skin condition, psoriasis. Palmoplantar pustulosis have symptoms such as crops of sterile pustules occurring on one or both hands and feet. Symptoms occur such as thickened, red, scaly skin that easily develops painful cracks. Palmoplantar pustulosis varies in severity and may continue for many years.
China Palmoplantar Pustulosis (PPP) Market Dynamics
Drivers
- Availability of Diverse Treatments for PPP
There are numerous treatment options that are available for treating patients suffering from PPP. Light therapy is a treatment that combines a medicine known as psoralen with a special form of ultraviolet light. Other treatments such as retinoids, biologic treatments such as adalimumab (Humira), brodalumab (Siliq), certolizumab pegol (Cimzia) etanercept (Enbrel). Other options include enzyme inhibitor, Methotrexate aryl hydrocarbon receptor (AHR) agonist are also useful. Thus, all these treatment options help in faster recovery of the patients impacting the market growth positively.
- Increasing Prevalence of Psoriasis
The prevalence of psoriasis varies between 0.09% and 11.4%, making psoriasis a common health problem in China. The prevalence of psoriasis is 0.47% in China, showing an upward trend from 0.12%. Psoriasis has equal gender incidence that can occur at any age. In China, the incidence of psoriasis ranges from 0.44 to 0.54%, with around 97% of patients having psoriasis vulgaris and 28% of patients reporting a family history. Thus, this factor boosts the market growth.
Opportunities
- Increasing Demand For Cyclosporine
There is a wide usage of cyclosporine in the treatment of palmoplantar pustulosis. Cyclosporine suppress the immune system, and is used n for serious cases that do not respond to other treatments. Cyclosporine is available in varied forms such as in the form of an oral capsule, an oral solution, eye drops, and an injectable form. It shows rapid improvement and quicker recovery. Thus, this factor increases the market growth.
- Increasing Collaborations and Associations by Several Market Players
Numerous product launch and agreement are also initiated by many companies’ globally which are also increasing the palmoplantar pustulosis (PPP) market. For instance, Zydus Pharmaceuticals, Inc. acquired the Heinz India, a top player in the healthcare domain, with a very strong distribution network over the 800 distributors in January 2019. This acquisition thus increased the company’s product sales and enabled it to generate more revenue. Thus, this factor increases the market growth.
Restraints/Challenges
- Increased Expenditure of Treatment for PPP
The rising expenditure associated with the varied treatment and diagnostic options of PPP hinder the market growth. This disease demands prolonged treatment many a times which increases the overall cost which is not that feasible for people belonging to underdeveloped and developing regions. This impedes the market growth.
This palmoplantar pustulosis (PPP) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the palmoplantar pustulosis (PPP) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
China Palmoplantar Pustulosis (PPP) Market Scope
The palmoplantar pustulosis (PPP) market is segmented on the basis of disease type, severity, diagnosis, treatment, population type, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- Type A
- Type B
Severity
- Mild-Moderate
- Moderate-Severe
Diagnosis
- Laboratory Tests
- Skin Biopsy
Treatment
- Emollients
- Topical Steroids
- Coal tar
- Phototherapy
Population Type
- Children
- Adults
Route of Administration
- Oral
- Topical
- Parenteral
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Competitive Landscape and China Palmoplantar Pustulosis (PPP) Market Share Analysis
The palmoplantar pustulosis (PPP) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, China presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to palmoplantar pustulosis (PPP) market.
Key players operating in the palmoplantar pustulosis (PPP) market include:
- Novartis AG (Switzerland)
- Lilly (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Bristol-Myers Squibb Company (U.S.)
- AstraZeneca (U.K.)
- GSK plc (U.K.)
- Merck & Co., Inc. (U.S.)
- Amgen inc. (U.S.)
- AnGes, Inc. (Japan)
- Johnson & Johnson Private Limited (U.S.)
- AbbVie Inc. (U.S.)
- Perrigo Company plc (Ireland)
- WOCKHARDT (India)
- Bausch Health Companies Inc. (Canada)
- Viatris Inc. (U.S.)
- Amneal Pharmaceuticals LLC. (U.S.)
- Xiromed (U.S.)
- Encube Ethicals Private Limited (U.S.)
SKU-